0001104659-23-000909.txt : 20230104 0001104659-23-000909.hdr.sgml : 20230104 20230104170121 ACCESSION NUMBER: 0001104659-23-000909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230104 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 23507599 BUSINESS ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9319 MAIL ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 8-K 1 tm231617d1_8k.htm FORM 8-K
0001697532 false 0001697532 2023-01-04 2023-01-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 4, 2023 

 

APPLIED THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38898   81-3405262
(State or Other Jurisdiction of
Incorporation)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

545 Fifth Avenue, Suite 1400
New York, NY 10017		  

10017

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code:  (212) 220-9226

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company               x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      x

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which
registered

Common stock   APLT   The Nasdaq Stock Market LLC

 

 

 

 

 

 

Item 1.01. Entry Into a Material Definitive Agreement.

 

On January 3, 2022, Applied Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Exclusive License and Supply Agreement (the “Agreement”) with Mercury Pharma Group Limited (trading as Advanz Pharma Holdings), a company organized and existing under the laws of England and Wales (“ADVANZ PHARMA”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe. Pursuant to the Agreement, the Company granted ADVANZ PHARMA the exclusive right and license to commercialize drug products containing AT-007 (also known as govorestat), the Company’s proprietary Aldose Reductase Inhibitor (ARI) (the “Licensed Product”), for use in treatment of sorbitol dehydrogenase deficiency (“SORD”) and galactosemia in humans (each, a “Licensed Indication”) in the European Economic Area, Switzerland and the United Kingdom (the “Territory”). The Company also grants ADVANZ PHARMA a right of negotiation and “most-favored nation” rights with respect to acquiring the European commercialization rights for any additional indications for which the Licensed Product may be developed in the future (or any other products the Company may develop solely to the extent used for the Licensed Indications).

 

ADVANZ PHARMA is required to use commercially reasonable efforts to launch and commercialize the Licensed Products in the major markets in the Territory in each Licensed Indication following, and subject to, receipt of marketing authorization therein. Under the Agreement, ADVANZ PHARMA agrees to pay the Company (i) an upfront payment of EUR 10 million (approx. USD $10.6 million), and certain development milestone payments upon clinical trial completions and receipt of marketing authorization in the Territory, as well as certain commercial milestone payments, totaling EUR 134 million (approx. USD $142.2 million) in the aggregate, and (ii) royalties of 20% of net sales of the Licensed Product. Such royalty rate will be payable on a country-by-country basis until the later of (i) the expiration of the licensed patents covering the composition of matter of AT-007, or (ii) 10 years after the European Medicines Agency’s grant of marketing authorization for the Licensed Product. The royalties are subject to certain deductions, including certain secondary finishing costs, certain step-in establishment costs and a portion of fees for any potential third party patent licenses if applicable in the future. Following the initial term of the license, as described above, the royalty rate shall be reduced to 10% and shall continue in perpetuity unless the Agreement is terminated in various circumstances in accordance with its terms.

 

Certain of the patents licensed to ADVANZ PHARMA under the Agreement are sub-licensed from the University of Miami and Columbia University, and thus remain subject to certain obligations of the Company (including royalty obligations) to such institutions.

 

Under the Agreement, the Company remains responsible for development of the Licensed Product, and must conduct such development through grant of marketing authorizations in the Licensed Indications in the Territory and as otherwise required under such marketing authorization, in accordance with any timeframe required by regulatory authorities. The Company retains sole responsibility for the conduct of all clinical trials (subject in some circumstances to cost-sharing with ADVANZ PHARMA), unless the Company provides ADVANZ PHARMA prior consent to conduct certain studies following marketing authorization, or ADVANZ PHARMA exercises certain step-in rights (as described below). The Company also agrees to manufacture and supply the Licensed Product in bulk form to ADVANZ PHARMA. ADVANZ PHARMA is responsible for secondary packaging and release for the Territory.

 

The Agreement includes indemnification obligations on the part of both parties for third-party claims arising out of, among other things, a breach of the Agreement; an election by the other party not to initiate a recall; gross negligence or willful misconduct; and violation of applicable laws. In addition, both parties have agreed to indemnification obligations for third party liability product liability claims and certain exclusions from liability disclaimers, such as for breaches of confidentiality, death or personal injury caused by negligence or willful default.

 

In certain circumstances, including in the event of specified supply shortages, bankruptcy and certain other financial events, a force majeure event lasting more than three months, or termination as a result of the Company’s gross negligence or willful misconduct, ADVANZ PHARMA may exercise certain step-in rights. Such step-in rights include the ability for ADVANZ PHARMA to perform its own supply arrangements, and in some cases, specified development rights in the Licensed Indications in the Territory and assignment of certain contract rights. In all such circumstances, ADVANZ PHARMA must continue to pay royalties and milestone payments. ADVANZ PHARMA may recoup certain of its manufacturing and development establishment costs, and deduct such costs from royalties.

 

 

 

 

The Company may terminate the Agreement upon certain specified events, including ADVANZ PHARMA’s failure to launch or achieve certain sales threshold for the Licensed Product in major markets within a certain timeframe, or if ADVANZ PHARMA challenges a licensed patent, and either party may terminate the Agreement upon the other party’s material breach or insolvency, certain material safety issues or a force majeure event of the other party lasting longer than six months. ADVANZ PHARMA may also terminate the agreement if the Licensed Product does not receive marketing authorization for use in a Licensed Indication in any country in the Territory by a specified date, or in the event of the Company’s gross negligence or willful misconduct (subject to a cure period).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APPLIED THERAPEUTICS, INC.
     
Dated: January 4, 2023 By: /s/ Shoshana Shendelman
  Name: Shoshana Shendelman
  Title: President and Chief Executive Officer

 

 

 

 EX-101.SCH 2 aplt-20230104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 aplt-20230104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 aplt-20230104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 04, 2023
Entity File Number 001-38898
Entity Registrant Name APPLIED THERAPEUTICS, INC.
Entity Central Index Key 0001697532
Entity Tax Identification Number 81-3405262
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 545 Fifth Avenue
Entity Address, Address Line Two Suite 1400
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10017
City Area Code 212
Local Phone Number 220-9226
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol APLT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 6 tm231617d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001697532 2023-01-04 2023-01-04 iso4217:USD shares iso4217:USD shares 0001697532 false 8-K 2023-01-04 APPLIED THERAPEUTICS, INC. DE 001-38898 81-3405262 545 Fifth Avenue Suite 1400 New York NY 10017 212 220-9226 false false false false true true Common stock APLT NASDAQ EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "F()%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " IB"160S2KANX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TD7#Z';B^))07!!\1:2V=U@DX9DI-VW-ZV[740?P&-F_GSS M#4QKHC)#PNY+HE0FOLA>4WEF0X0M?G0 M!P3)^2UX)&TU:9B!55R)K&NM42:AIB&=\=:L^/B9^@5F#6"/'@-E$+4 ULT3 MXVGJ6[@"9AAA\OF[@'8E+M4_L4L'V#DY9;>FQG&LQV;)E1T$O#T]OBSK5BYD MTL%@^96=HE/$+;M,?FWN[G621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M "F()%8RB/(=@ 0 +(1 8 >&PO=V]R:W-H965T&UL MC9AO<^(V$,:_BL:=N6EGDF"+OTF!&4)(CUZ.\P72FVNG+X0M0'.V1"4Y)-^^ M*T-LFIHU;Q+;>!]^WET_6M'?*?W#;#BWY"5-I!EX&VNW-XV&B38\9>9*;;F$ M3U9*I\S"J5XWS%9S%N=!:=*@OM]II$Q(;]C/KX5ZV%>9383DH28F2U.F7V]Y MHG8#+_#>+CR*]<:Z"XUA?\O6?,[MTS;4<-8H5&*1WM.," M\CO^$'QGCHZ)>Y2E4C_>+XCX@F/K)-@\.^9CWF2."7@^.<@ZA7?Z0*/ MC]_4[_.'AX=9,L/'*ODF8KL9>#V/Q'S%LL0^JMU'?GB@MM.+5&+ROV2WO[?M M>R3*C%7I(1@(4B'W_]G+(1%' ;1[(H > FC.O?^BG/*.63;L:[4CVMT-:NX@ M?]0\&N"$=%696PV?"HBSP[%ZYKK?L"#E+C2B0]CM/HR>"/N=R2OBMRX(]6GS MO^$-("@P:(%!<[TFAD'^&BV-U5"HOZN(]@JM:@77O3=FRR(^\* ]#=?/W!M^ M^"GH^+\B?,V"KXFI#^]4E$$O6K)XW?(J.#R\=_D)@6@5$"U4900$<4YQG[!U M%04>OV*)X0A'N^!HGY>,D&NA8C*1,8'FJ\P+KI2W4=Y'=8W4*=@ZJ.)$6F%? MR;U(.)EEZ;*ZN7$-WP\NF[W>=0_AZ18\W7-X'OE:N-:&I,U86IDI7&<4A@_3 MR1U9?)P\CL+)TV(ZGE^0Z6Q\A4#V"LC>.9!CJ*EF"9G*F+^03_RU"A-7\B%W MG>MNNTD1K.L"Z_H MX#[R15:3X9+M5AO>L)7=D-$SEQGF*4&Y @2H@>.'8G4&=%VHG*^EPN1F,+-]A9,'8RJ4AP+W]/5O1A*%6ST)&U67& M-6??,;1RM0APDW^/%BICP67^%-O3;P:N&(#+=#&V4]K!B,HU(<"M_)L6UG()B4G33!Z< MUU12X4)U8T=0K@3!5>IX:.G_%'?H4//+"-+# MX?W:3X" L3 MFEJ1@/Z\_(7,>91!OU5.'#5*KC]A)("=4H19*2UMGN*^O- L=BTV?TV7JK+! M:@1&X<,"(RE-G>(&_)85,GF)-DRN^CO=OH\)C,%+Z(B3X83N^&0.^N:/B90 M5VE$/C_N-RZ5L/AWG()M'.W W:\9GYG+CB$)7X&.?]6%'.C]#P3[$ZNV^:9\ MJ2QL\?/##6?P;KH;X/.54O;MQ.WSBY]IAO\"4$L#!!0 ( "F()%:?H!OP ML0( .(, - >&PO9KEMWDOSA MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!> M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V& M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V; MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \ M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^ M8* \^>Q\ETWLJ.?]74_P$4$L#!!0 M ( "F()%:7BKL

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://appliedtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm231617d1_8k.htm aplt-20230104.xsd aplt-20230104_lab.xml aplt-20230104_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm231617d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm231617d1_8k.htm" ] }, "labelLink": { "local": [ "aplt-20230104_lab.xml" ] }, "presentationLink": { "local": [ "aplt-20230104_pre.xml" ] }, "schema": { "local": [ "aplt-20230104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "APLT", "nsuri": "http://appliedtherapeutics.com/20230104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm231617d1_8k.htm", "contextRef": "From2023-01-04to2023-01-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://appliedtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm231617d1_8k.htm", "contextRef": "From2023-01-04to2023-01-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-000909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-000909-xbrl.zip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end